FDA warns Living Tree Community Foods that its RTE nut and seed butters had uncontrolled pathogen/allergen hazards and drug claims.
What happened
FDA inspected the Berkeley facility from February 13 through March 17, 2023, and reviewed product labels and the company website on October 11, 2023. FDA found serious current good manufacturing practice (CGMP) and preventive-control violations for ready-to-eat organic seed and nut butters, including uncontrolled pathogen and allergen hazards; a March 8, 2023 Walnut Butter sample showed sesame. FDA also cited unapproved-drug claims for Sesame Tahini and misbranded nutrition labels.
What FDA found
FDA said the hazard analysis did not treat Salmonella and E. coli in raw tree nuts and seeds as hazards needing a preventive control and did not adequately verify suppliers.
21 CFR 117.130(a)(1); 21 CFR 117.405(a)(1); 21 CFR 117.410; 21 CFR 117.430(b)FDA said allergen cross-contact was not adequately controlled on shared equipment, and sesame was found in a Walnut Butter sample after sesame was sliced on the same machine.
21 CFR 117.130(a)(1); 21 CFR 117.135(c)(2)(ii)FDA said mycotoxins such as aflatoxins in tree nuts and seeds were not controlled through a supply-chain program or adequate supplier verification.
21 CFR 117.405(a)(1); 21 CFR 117.410; 21 CFR 117.430FDA observed equipment that was not adequately cleanable or maintained and an employee who did not wash hands after touching a trash can lid before handling food and gloves.
21 CFR 117.40(a)(1); 21 CFR 117.10(b)(3)FDA said website claims for Sesame Tahini about cancer and calcium made it an unapproved new drug and a misbranded drug without adequate directions for use.
21 U.S.C. § 321(g)(1)(B); 21 U.S.C. § 321(p); 21 U.S.C. § 352(f)(1)FDA said nutrition labels and nutrient content claims for several butters did not meet required food labeling rules.
21 U.S.C. § 343(q); 21 CFR 101.9; 21 U.S.C. § 343(r)(1)(A)
What FDA wants
FDA tells the company to correct the cited current good manufacturing practice (CGMP), preventive-control, labeling, and drug-claim violations; the provided letter does not state a response deadline.
Who should pay attention
- nut and seed butter manufacturers using shared equipment
- food brands relying on supplier pathogen controls
- retailers and consumers of organic RTE nut butters
This is a summary. Read the original letter on fda.gov.